Baroda BNP Paribas Large & Mid Cap Fund
(An open ended scheme investing in both
large cap and mid cap stocks)
Baroda BNP Paribas Large & Mid Cap Fund
(An open ended scheme investing in both
large cap and mid cap stocks)
May 2025

May 2025


Investment Objective

The primary objective of the Scheme is to seek long term capital growth through investments in both large cap and mid cap stocks. However, there is no assurance that the investment objective of the Scheme will be achieved

NAV Details (As on May 30, 2025)
Regular Plan - IDCW Option : ₹19.1024
Regular Plan - Growth Option : ₹26.4972
Direct Plan - IDCW Option : ₹21.7799
Direct Plan - Growth Option : ₹28.4202
Benchmark Index (Tier 1)

BSE 250 Large & Mid Cap TRI

Date of Allotment

September 04, 2020

Fund Manager
Fund Manager Managing fund since Experience
Mr. Sanjay Chawla 04-Sep-20 33 years
Mr. Kirtan Mehta 01-Jan-25 26 years
Load Structure

Exit Load: • If units are redeemed up to 10% of the units held on or before 365 days from the date of allotment - Nil • If units are redeemed over and above the 10% limit on or before 365 days from the date of allotment - 1% of the applicable Net Asset Value (NAV) • If units of scheme are redeemed after 365 days from the date of allotment - Nil.
For detailed load structure please refer Scheme Information Document.


Lumpsum Details

Minimum Amount: Lumpsum investment:
₹ 5,000 and in multiples of ₹ 1 thereafter.
Minimum Additional Application Amount:₹ 1,000 and in multiples of ₹ 1 thereafter.


Monthly AAUM## As on May 30, 2025 : ₹ 1,545.46 Crores
AUM## As on May 30, 2025 : ₹ 1,581.02 Crores

## including inter-scheme Investments, if any, by other schemes of Baroda BNP Paribas Mutual Fund, as may be applicable

EQUITY HOLDINGS% of Net Assets
Banks 20.88%
HDFC Bank Limited 6.77%
ICICI Bank Limited 5.49%
Kotak Mahindra Bank Limited 3.28%
The Federal Bank Limited 3.13%
Bank of Baroda 2.21%
Pharmaceuticals & Biotechnology 9.75%
Sun Pharmaceutical Industries Limited 2.65%
Concord Biotech Limited 1.99%
Alkem Laboratories Limited 1.77%
Ajanta Pharma Limited 1.67%
Divi's Laboratories Limited 1.67%
Finance 7.88%
CRISIL Limited 3.07%
Shriram Finance Limited 2.83%
PNB Housing Finance Limited 1.98%
Petroleum Products 5.56%
Hindustan Petroleum Corporation Limited 2.86%
Reliance Industries Limited 2.70%
IT - Software 5.55%
Infosys Limited 2.82%
Tata Consultancy Services Limited 1.53%
Hexaware Technologies Limited 1.20%
Insurance 4.10%
Max Financial Services Limited 2.14%
ICICI Lombard General Insurance Company Limited 1.96%
Retailing 3.97%
Info Edge (India) Limited 1.81%
FSN E-Commerce Ventures Limited 1.41%
Eternal Limited 0.75%
Electrical Equipment 3.57%
GE Vernova T&D India Limited 2.06%
ABB India Limited 1.51%
Telecom - Services 3.40%
Bharti Airtel Limited 3.40%
Industrial Manufacturing 3.03%
Kaynes Technology India Limited 3.03%
Auto Components 3.01%
Samvardhana Motherson International Limited 1.74%
ZF Commercial Vehicle Control Systems India Limited 1.27%
Consumer Durables 2.96%
Blue Star Limited 1.84%
Dixon Technologies (India) Limited 1.12%
Textiles & Apparels 2.64%
Page Industries Limited 2.64%
Construction 2.35%
Larsen & Toubro Limited 1.33%
Afcons Infrastructure Limited 1.02%
Power 2.19%
NTPC Green Energy Limited 1.27%
Power Grid Corporation of India Limited 0.92%
Food Products 2.09%
Britannia Industries Limited 2.09%
Oil 2.09%
Oil India Limited 2.09%
Financial Technology (Fintech) 1.85%
PB Fintech Limited 1.85%
Leisure Services 1.83%
The Indian Hotels Company Limited 1.83%
Cement & Cement Products 1.81%
JK Cement Limited 1.81%
Transport Services 1.18%
InterGlobe Aviation Limited 1.18%
Healthcare Services 1.18%
Jupiter Life Line Hospitals Limited 1.18%
Agricultural, Commercial & Construction Vehicles 1.16%
Escorts Kubota Limited 1.16%
Agricultural Food & other Products 1.09%
AWL Agri Business Limited 1.09%
TOTAL EQUITY HOLDING 95.12%
Total Fixed Income Holdings
TREPS, Cash & Other Net Current Assets 4.88%
GRAND TOTAL 100.00%

Investment in Top 10 scrips constitutes 36.68% of the portfolio


For SIP Performance please click here

For Scheme Performance please click here


Pursuant to distribution under Income Distribution cum Capital Withdrawal (‘IDCW’) option, NAV of the IDCW option of the scheme(s) would fall to the extent of payout and statutory levy (if applicable). The amounts under IDCW options can be distributed out of investors capital (Equalization Reserve), which is part of sale price that represents realized gains. Past performance may or may not be sustained in future. The above stated distribution rate per unit is net distribution rate after deducting applicable taxes. The above distribution rates are on face value of ₹ 10 per unit.

TER - Regular Plan (%) 2.11%
TER - Direct Plan (%) 0.84%
Portfolio Turnover Ratio 0.86
Standard Deviation* 14.99%
Beta* 0.98
Sharpe Ratio* 1.00
Sharpe Ratio (annualised), Standard Deviation (annualised) and Beta are based on last 36 monthly data points.

* The information contained in this report has been obtained from sources considered to be authentic and reliable. This quantitative data does not purport to be an offer for purchase and sale of mutual fund units.
The risk free rate of return considered for calculation of Sharpe ratio is 5.86%, as per 1 day MIBOR rate on the last business day of the month.

No of Stocks 45
Portfolio RoE (%) 18.10
EPS Growth (%) 29.68

This product is suitable for investors who are seeking*:

➤ Capital appreciation over long term.
➤ Investment predominantly in equity and equity related instruments of large and midcap stocks.

*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.

Scheme Riskometer^^
Investors understand that their principal will be at Very High risk


Benchmark (Tier 1) Riskometer^
Benchmark riskometer is at Very High risk


^^Riskometer For Scheme: basis it’s portfolio, ^Riskometer For Benchmark (BSE 250 Large & Mid Cap TRI): basis it’s constituents; As on May 30, 2025

For complete portfolio, kindly refer the website https://www.barodabnpparibasmf.in/

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.